Patents Examined by Simon J. Oh
-
Patent number: 7025984Abstract: The present invention is for compositions and methods for managing the body weight of a subject using said compositions. Weight management, particularly weight gain and loss, is effectuated by producing a sensation of satiety in said subjects. The method of managing body weight includes administering the composition prior to food consumption, concurrent with food consumption, as replacement for food consumption and combinations thereof.Type: GrantFiled: June 26, 2000Date of Patent: April 11, 2006Assignee: The Procter & Gamble CompanyInventors: Ronald James Jandacek, Gary Robert Kelm, Satinder Singh Bharaj, Jorge Villanueva Penafiel
-
Patent number: 7025979Abstract: A formulation for male contraception comprising a progestin possessing both estrogenic and androgenic properties is remarkably effective for spermatogenesis suppression in males. The progestin Norethisterone (NET), particularly its derivatives Norethisterone acetate and Norethisterone enanthate in sufficient doses induce oligozoospermia or azoospermia in males. Formulations further comprising an androgen, such as a testosterone derivative such as a testosterone ester, particularly testosterone undecanoate, are especially effective male contraceptive formulations.Type: GrantFiled: January 19, 2001Date of Patent: April 11, 2006Assignee: Schering AGInventors: Eberhard Nieschlag, Axel Kamischke, Michael Oettel, Alexander Ruebig, Ekkerhard Schillinger, Ursula-Friederike Habenicht
-
Patent number: 7022343Abstract: Methods for the simple, reliable application and local controlled release of selected anti-arrhythmia drugs from a hydrogel applied to or polymerized on the tissues of the heart or its vessels, especially in conjunction with cardiac bypass or other cardiac surgery, have been developed. The anti-arrhythmia drugs are incorporated into hydrogels that biodegrade and adhere to the tissues to which the anti-arrhythmic drugs are to be delivered. The hydrogels may be formed in vitro or in vivo. In a preferred embodiment, the drugs are effective to lengthen atrial effective refractory period. A particularly preferred drug is amiodarone.Type: GrantFiled: December 27, 2001Date of Patent: April 4, 2006Assignee: Genzyme CorporationInventors: C. Michael Philbrook, James W. Burns, Kevin C. Skinner, Robert J. Miller
-
Patent number: 7011841Abstract: Porous materials are disclosed having densities of at least about 6 pounds per cubic foot (96.1 kg/m3). The materials comprise silica and/or alumina. The porous materials are useful as supports for binding various chemical and biological molecules. The materials are useful as supports for analytical processes such as ELISA, blotting, and hybridization assays. The materials can be used as reinforcement agents for organic, inorganic, or metallic materials.Type: GrantFiled: March 24, 2001Date of Patent: March 14, 2006Inventor: Mark B. Lyles
-
Patent number: 7004321Abstract: The invention relates to a packaging of products which are additionally packed in a pouch (2) in order to protect the same, whereby the packaging is comprised of at least two pouches. The products placed in these pouches can be identical or different. These products are to be preferably removed and used in a predetermined order.Type: GrantFiled: March 9, 2000Date of Patent: February 28, 2006Assignee: LTS Lohmann Therapie-Systeme AGInventors: Detlef Palm, Ronald Hackbarth, Michael Heberle, Detlev Neuland
-
Patent number: 7001619Abstract: The present invention relates to a composition useful for hepatocurative effect against CYP 450 bio-activation hepatotoxicity induced by drugs, said composition comprising an extract from Emblica officinalis and optionally pharmaceutically acceptable additives and method of treating drug induced hepatotoxicity.Type: GrantFiled: March 27, 2002Date of Patent: February 21, 2006Assignee: Council of Scientific and Industrial ResearchInventors: Rakesh Kamal Johri, Sheikh Tasaduq Abdullah, Kuldeep Singh, Devinder Kumar Gupta, Bal Krishan Kapahi, Dilip Manikrao Mondhe, Satinder Mohan Jain, Om Parkash Suri, Kasturi Lal Bedi, Ghulam Nabi Qazi
-
Patent number: 7001606Abstract: The invention relates to biocidal polymers based on guanidine salts characterized in that they are representatives of a number of polyoxyalkylene guanidines and their salts and are a product of a polycondensation of guanidine salts with diamines which include two amino groups and polyoxyalkylene chains therebetween. In addition to a high bactericidity, these new polymer products are provided with a relatively low toxicity, an increased hydrophily, a quick and complete dilution in water, increased values of relative molar mass, and distinct characteristics of polymer surface active substances.Type: GrantFiled: May 8, 2001Date of Patent: February 21, 2006Assignee: P.O.C. Oil Industry Technology Beratungsges m.b.H.Inventors: Oskar J. Schmidt, Andreas Schmidt, Dimitri Toptchiev
-
Patent number: 6998139Abstract: The invention relates to a method for reducing bitterness of bitter drugs, which does not cause delay of release rate, does not show reduction of bioavailability in comparison with conventional pharmaceutical preparations and, due to the use of additives generally used in the field of pharmaceutical preparation, has high practical value, and to intrabuccally quick disintegrating tablets having reduced bitterness of bitter drugs. Illustratively, it relates to an intrabuccally quick disintegrating tablet which comprises a bitter drug and a water-insoluble substance having an average particle size of 30 ?m or less, wherein the water-insoluble substance disperses as particles on the tongue surface prior to the release of the bitter drug.Type: GrantFiled: March 14, 2002Date of Patent: February 14, 2006Assignee: Astellas Pharma Inc.Inventors: Masahiro Yanagisawa, Takao Mizumoto
-
Patent number: 6977249Abstract: In a process for producing an iron-dextran compound for use in parenteral treatment of iron-deficiency in humans or animals a stable compound of desired relatively low molecular weight is obtained by using first hydrogenation and then oxidation to convert reducing terminal groups on the dextran molecules before reaction with the iron. By varying the ratio of hydrogenated groups to oxygenated groups the average molecular weight of the resulting iron-dextran compound can be varied.Type: GrantFiled: July 29, 1999Date of Patent: December 20, 2005Assignee: Pharmacosmos Holding A/SInventors: Hans Berg Andreasen, Lars Christensen
-
Patent number: 6977085Abstract: The present invention provides a method for preparing a suspension of a pharmaceutically-active compound, the solubility of which is greater in a water-miscible first organic solvent than in a second solvent which is aqueous. The process includes the steps of: (i) dissolving a first quantity of the pharmaceutically-active compound in the water-miscible first organic solvent to form a first solution; (ii) mixing the first solution with the second solvent to precipitate the pharmaceutically-active compound; and (iii) seeding the first solution or the second solvent or the pre-suspension.Type: GrantFiled: October 19, 2001Date of Patent: December 20, 2005Assignee: Baxter International Inc.Inventors: Jane Werling, James E. Kipp, Rajaram Sriram, Mark J. Doty
-
Patent number: 6974816Abstract: The invention relates to a combination of (a) an inhibitor of platelet-derived growth factor (PDGF) activity and (b) a vector for vascular endothelial growth factor (VEGF-, especially VEGF-C) gene transfer, a pharmaceutical preparation comprising (a) and (b) in combination together with a pharmaceutically acceptable carrier material; a product comprising (a) and (b) as defined above and optionally a pharmaceutically acceptable carrier material, for simultaneous, chronologically staggered or separate use; a method of administering or the use of said combination or product for the treatment of endothelial damage; and/or to the use of (a) and (b) for the manufacture of said pharmaceutical preparation or product for the treatment of endothelial damage.Type: GrantFiled: August 23, 2002Date of Patent: December 13, 2005Assignees: Licentia Ltd., Ludwig Institiute for Cancer ResearchInventors: Kari Alitalo, Carl-Henrik Heldin, Olli Leppänen, Arne Östman, Seppo Ylā-Herttuala
-
Patent number: 6951656Abstract: The present invention provides a method for preparing submicron sized particles of an organic compound, the solubility of which is greater in a water-miscible first solvent than in a second solvent which is aqueous, the process including the steps of: (i) dissolving the organic compound in the water-miscible first solvent to form a solution, (ii) mixing the solution with the second solvent to define a pre-suspension; and (iii) adding energy to the pre-suspension to form particles having an average effective particle size of less than about 2 ?m.Type: GrantFiled: September 17, 2001Date of Patent: October 4, 2005Assignee: Baxter International Inc.Inventors: James E. Kipp, Joseph Chung Tak Wong, Mark J. Doty, Christine L. Rebbeck, Sean Brynjelsen
-
Patent number: 6949257Abstract: Spontaneously dispersible pharmaceutical compositions comprising a piperidine, e.g. 1-acylpiperidine Substance P Antagonist and its use in the treatment of CNS disorders, e.g. depression and social phobia, and respiratory diseases, e.g. asthma and chronic bronchitis.Type: GrantFiled: March 4, 2003Date of Patent: September 27, 2005Assignee: Novartis AGInventors: Steffen Lang, Kurt Liechti
-
Patent number: 6949261Abstract: An isolate from the leaves of Gymnema sylvestre, having a specified molecular weight, is useful for the treatment of diabetes. The isolate has a molecular weight at least about 3000 Daltons as determined by molecular weight cut-off filtration. Glucose metabolism in a human patient is regulated by dosage forms that contain the aforesaid isolate from the leaves of Gymnema sylvestre, optionally in combination with a non-metabolizable polysaccharide such as the exudate of Sterculia urens.Type: GrantFiled: November 12, 2002Date of Patent: September 27, 2005Assignee: Ayurvedic-Life International, LLCInventor: Arun K. Chatterji
-
Patent number: 6946151Abstract: An oral composition, suitable as a hypoglycemic agent, includes an isolate from the leaves of Gymnema sylvestre, having a specified molecular weight. The isolate has a molecular weight at least about 3000 Daltons as determined by molecular weight cut-off filtration. Glucose metabolism in a human patient can be regulated by dosage forms that contain the aforesaid isolate from the leaves of Gymnema sylvestre, in combination with a non-metabolizable, water-swellable polysaccharide such as the exudate of Sterculia urens, and a water-soluble polysaccharide such as guar gum. Optionally, the present oral compositions can include a physiologically acceptable calcium source, a physiologically acceptable metal carbonate salt, a physiologically acceptable chromium salt, and/or a physiologically acceptable vanadium compound. In addition, antioxidants such as ascorbic acid, cholecalciferol, d-?-tocopherol, the carotenoids, lycopene, lutein, and the like, can be included as well.Type: GrantFiled: March 4, 2003Date of Patent: September 20, 2005Assignee: Ayurvedic-Life International, LLCInventor: Arun K. Chatterji
-
Patent number: 6939561Abstract: Provided are methods and compositions for reducing the toxicity of certain hydrophobic therapeutic agents, especially polyene antibiotics, in particular, Amphotericin B (AmB), and therapeutics such as paclitaxel, tamoxifen, an acylated prodrug or an acylated cis-platin, by incorporating these agents within micelles comprising an amphiphilic block-forming copolymer. Where the polyene is amphotericin B, desirably the spacer is an alkyl molecule of aabout 2 to about 8 carbon atoms, desirably 6 carbon atoms, and the core is an N-alkyl molecule of about 8 to about 28 carbon atoms, desirably 12 to 22 carbon atoms, advantageously, 12 to 18 carbon atoms, and as specifically embodied, 18 carbon atoms (stearate moiety). For the formulation of a larger polyene, the spacer and core are proportionately larger than those for amphotericin B. As specifically exemplified herein, the polymer backbone is a PEO of about 270 units with about 10-30 core-forming PLAA subunits, and advantageously about 14-24.Type: GrantFiled: June 28, 2002Date of Patent: September 6, 2005Assignee: Wisconsin Alumni Research FoundationInventors: Glen S. Kwon, John Samuel, Afsaneh Lavasanifar
-
Patent number: 6936274Abstract: This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance, an alditol, and a saccharide, and, optionally, additional pharmaceutically accepted excipients. Levothyroxine sodium is the preferred active drug substance, mannitol is the preferred alditol, and sucrose is the preferred saccharide. Additional preferred excipients include, for example, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and sodium lauryl sulfate.Type: GrantFiled: May 22, 2003Date of Patent: August 30, 2005Assignee: Mylan Pharmaceuticals, Inc.Inventors: Dwight D. Hanshew, Jr., David John Wargo
-
Patent number: 6933310Abstract: An object of the present invention is to provide a novel medicament with which motor neuron diseases can be treated. According to the present invention, there is provided a therapeutic agent for motor neuron diseases which comprises 3-methyl-1-phenyl-2-pirazoline-5-on or physiologically acceptable salts thereof as an active ingredient.Type: GrantFiled: November 13, 2000Date of Patent: August 23, 2005Assignee: Mitsubishi Pharma CorporationInventor: Ken Ikeda
-
Patent number: 6913759Abstract: A pharmaceutical composition having a gel consistency at room temperature and suitable for the treatment of a vaginal infection comprises, on a total composition weight basis, about 0.1 to about 3 weight percent of benzydamine hydrochloride, about 16 to about 35 weight percent of a polyoxyalkylene block copolymer, and about 2 to about 30 weight percent of propylene glycol, in water having a pH value in the range of about 3.5 to about 7. The weight ratio of water to polyoxyalkylene block copolymer in the composition is less than about 4:1. Optionally, the gel compositions can also contain glycerin, physiologically tolerable preservatives and buffers, as well as other pharmaceutically acceptable excipients.Type: GrantFiled: March 11, 2003Date of Patent: July 5, 2005Assignee: Curatek Pharmaceuticals Holding, Inc.Inventors: Robert J. Borgman, James E. Juul
-
Patent number: 6911217Abstract: A controlled release bead comprises: (i) a core unit of a substantially water-soluble or water-swellable inert material; (ii) a first layer on the core unit of a substantially water-insoluble polymer; (iii) a second layer covering the first layer and containing an active ingredient; and (iv) a third layer of polymer on the second layer effective for controlled release of the active ingredient, wherein the first layer is adapted to control water penetration into the core. A method of producing the controlled release bead is also disclosed.Type: GrantFiled: November 11, 1999Date of Patent: June 28, 2005Assignee: Pharmacia ABInventors: Torkel Gren, Anders Ringberg, Martin Wikberg, Randy J. Wald